Loading…
Loading…
As of 20 Nov 2026: NEULANDLAB ₹20,642.00 (m-cap ₹26,422 Cr, P/E 58.5) vs SAILIFE ₹1,800.70 (m-cap ₹38,355 Cr, P/E 101.4). Compare ROE, ROCE, growth, debt, dividends and 1-year returns.
As of · NSE prices; ratios from company filings
| Metric | NEULANDLAB | SAILIFE |
|---|---|---|
| Share price | ₹20,642.00 | ₹1,800.70 |
| Day change | −2.18% | +0.69% |
| Market cap | ₹26,422 Cr | ₹38,355 Cr |
| P/EPrice ÷ trailing 12-month earnings per share; blank for a loss. | 58.5 | 101.4 |
| P/BPrice ÷ book value per share. | 13.1 | 14.2 |
| ROEReturn on equity. | 21.2% | 15.4% |
| ROCEReturn on capital employed. | 26.0% | 20.0% |
| Sales growth (3Y CAGR) | 19.3% | 21.7% |
| Profit growth (3Y CAGR) | 30.0% | 227.0% |
| Debt to equity | 0.17 | 0.23 |
| Dividend yield | 0.16% | 0.00% |
| 1-year price return | +23.5% | +106.0% |
| Promoter holding | 32.3% | 34.5% |
| Industry | Pharmaceuticals | Pharmaceuticals |
Open in the compare tool for price charts from one month to five years, scorecards and more companies.
Each line states which company has the higher or lower figure; none of them is a recommendation.
Sai Life Sciences Ltd is larger, with a market cap of ₹38,355 Cr against ₹26,422 Cr for Neuland Laboratories Ltd as of 20 Nov 2026 — about 1.5 times the size.
Neuland Laboratories Ltd trades at a P/E of 58.5 against 101.4 for Sai Life Sciences Ltd as of 20 Nov 2026. A lower P/E alone does not make a share cheaper in value terms: growth, return on capital and debt differ between companies.
Jivani Markets does not give buy, sell or hold recommendations and is not a SEBI-registered investment adviser or research analyst. The table on this page lays out the facts side by side — price, valuation, returns on capital, growth, debt, dividends and promoter holding — so you can weigh them against your own goals, or with a SEBI-registered adviser.
Prices refresh every few minutes during market hours and ratios update when the companies report results. Each number is the same one shown on the two stock pages.